Liver carcinoma | Hepatocellular Carcinoma by BCLC Stage
Item
1. patients with a confirmed diagnosis of hcc according to the easl criteria for diagnosis, and staged according to the bclc criteria
boolean
C2239176 (UMLS CUI [1])
C3898888 (UMLS CUI [2])
Informed Consent
Item
2. subject is competent and willing to provide written informed consent in order to participate in the study
boolean
C0021430 (UMLS CUI [1])
Adult | Age
Item
3. adults (male or female) patients ≥ 18 years of age
boolean
C0001675 (UMLS CUI [1])
C0001779 (UMLS CUI [2])
ECOG performance status | Child-Pugh Classification
Item
4. ecog performance status 0-2 or child pugh classification is 0-11
boolean
C1520224 (UMLS CUI [1])
C4050412 (UMLS CUI [2])
Tumor Multinodular | Tumor Single nodule | Tumor size | Disease Bilobar | Measurable lesion Dimension Quantity
Item
5. multidonar or single nodular tumor ≥3-10cm, patients with bilobar disease who can be treated superselectively in a single session or both lobes able to be treated within 3-5 weeks. patient must have at least one tumor lesion that meets the following criteria: lesion can be accurately measured in at least one dimension according to mrecist criteria
boolean
C0027651 (UMLS CUI [1,1])
C0205416 (UMLS CUI [1,2])
C0027651 (UMLS CUI [2,1])
C2221193 (UMLS CUI [2,2])
C0475440 (UMLS CUI [3])
C0012634 (UMLS CUI [4,1])
C0444465 (UMLS CUI [4,2])
C1513041 (UMLS CUI [5,1])
C0439534 (UMLS CUI [5,2])
C1265611 (UMLS CUI [5,3])
Invasion Absent Blood Vessel Major | Invasion Absent Hepatic portal | Invasion Absent Hepatic vein | Invasion Absent Bile duct | MRI | CT
Item
6. no invasion in the major blood vessel (hepatic portal, hepatic vein) or bile duct by the mri or ct
boolean
C1269955 (UMLS CUI [1,1])
C0332197 (UMLS CUI [1,2])
C0005847 (UMLS CUI [1,3])
C0205164 (UMLS CUI [1,4])
C1269955 (UMLS CUI [2,1])
C0332197 (UMLS CUI [2,2])
C0227498 (UMLS CUI [2,3])
C1269955 (UMLS CUI [3,1])
C0332197 (UMLS CUI [3,2])
C0019155 (UMLS CUI [3,3])
C1269955 (UMLS CUI [4,1])
C0332197 (UMLS CUI [4,2])
C0005400 (UMLS CUI [4,3])
C0024485 (UMLS CUI [5])
C0040405 (UMLS CUI [6])
Hematologic function | Liver function | Renal function | Cardiac function
Item
7. proper blood, liver, renal, heart function: testing result within 2 weeks from registry of this study
boolean
C0221130 (UMLS CUI [1])
C0232741 (UMLS CUI [2])
C0232804 (UMLS CUI [3])
C0232164 (UMLS CUI [4])
Exclusion | Communicable Diseases Requirement Antibiotic therapy
Item
8. no current infections requiring antibiotic therapy
boolean
C0680251 (UMLS CUI [1])
C0009450 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0338237 (UMLS CUI [2,3])
Exclusion Criteria | Coumarin Anticoagulation Therapy | Blood Coagulation Disorders
Item
9. not actively on cumarin based anticoagulation or suffering from a known bleeding disorder
boolean
C0680251 (UMLS CUI [1])
C0010206 (UMLS CUI [2,1])
C0003281 (UMLS CUI [2,2])
C0005779 (UMLS CUI [3])
Measurable Disease
Item
10. measurable disease per the response evaluation criteria in solid tumors (mrecist)
boolean
C1513041 (UMLS CUI [1])
Life Expectancy
Item
11. expected survival more than 6 months
boolean
C0023671 (UMLS CUI [1])
ECOG performance status | Child-Pugh Classification | ASA physical status class
Item
1. ecog performance status >2; or child-pugh class c11 or more, or asa class 5
boolean
C1520224 (UMLS CUI [1])
C4050412 (UMLS CUI [2])
C0578808 (UMLS CUI [3])
Serum total bilirubin measurement
Item
2. bilirubin levels >3 mg/dl
boolean
C1278039 (UMLS CUI [1])
Liver carcinoma | Invasion Large vessel | Invasion Bile duct | Liver carcinoma Diffuse | Spread Extrahepatic
Item
3. hcc with large vessel or biliary duct invasion, diffuse hcc or extrahepatic spread
boolean
C2239176 (UMLS CUI [1])
C1269955 (UMLS CUI [2,1])
C0225990 (UMLS CUI [2,2])
C1269955 (UMLS CUI [3,1])
C0005400 (UMLS CUI [3,2])
C2239176 (UMLS CUI [4,1])
C0205219 (UMLS CUI [4,2])
C0332261 (UMLS CUI [5,1])
C1517058 (UMLS CUI [5,2])
Medical contraindication Specified Any
Item
4. patients in which any of the following are contraindicated or present:
boolean
C1301624 (UMLS CUI [1,1])
C0205369 (UMLS CUI [1,2])
C1552551 (UMLS CUI [1,3])
Doxorubicin
Item
the use of doxorubicin
boolean
C0013089 (UMLS CUI [1])
MRI
Item
mri
boolean
C0024485 (UMLS CUI [1])
Hepatic embolisation
Item
hepatic embolization procedures
boolean
C0744813 (UMLS CUI [1])
White Blood Cell Count procedure
Item
wbc < 3000 cells/mm3
boolean
C0023508 (UMLS CUI [1])
Neutrophil count
Item
neutrophil < 1500 cells/mm3
boolean
C0200633 (UMLS CUI [1])
Cardiac ejection fraction Radionuclide Ventriculography | Cardiac ejection fraction Echocardiography | Cardiac ejection fraction MRI
Item
cardiac ejection fraction < 50 percent assessed by isotopic ventriculography, echocardiography or mr
boolean
C0232174 (UMLS CUI [1,1])
C0034610 (UMLS CUI [1,2])
C0232174 (UMLS CUI [2,1])
C0013516 (UMLS CUI [2,2])
C0232174 (UMLS CUI [3,1])
C0024485 (UMLS CUI [3,2])
Serum creatinine raised
Item
elevated creatinine greater than or equal to 2.5 mg/dl
boolean
C0700225 (UMLS CUI [1])
Clotting test Impaired | Platelet Count measurement | PT-INR
Item
impaired clotting test (platelet count < 5 x 104/mm3, pt-inr > 2.0)
boolean
C1277719 (UMLS CUI [1,1])
C0221099 (UMLS CUI [1,2])
C0032181 (UMLS CUI [2])
C1821762 (UMLS CUI [3])
Aspartate aminotransferase increased | Alanine aminotransferase increased
Item
ast and/or alt >5x uln or, when greater >250 u/l
boolean
C0151904 (UMLS CUI [1])
C0151905 (UMLS CUI [2])
Hepatofugal flow
Item
known hepatofugal blood flow
boolean
C4086746 (UMLS CUI [1])
Arteriovenous fistula
Item
arterio-venous shunt
boolean
C0003855 (UMLS CUI [1])
Portasystemic shunt Arterial | Other Coding
Item
arterio-portal shunt
boolean
C0948900 (UMLS CUI [1,1])
C0221464 (UMLS CUI [1,2])
C3846158 (UMLS CUI [2])
Main portal venous trunk Occlusion
Item
main stem portal vein occlusion(point 6 in inclusion criteria)
boolean
C1183135 (UMLS CUI [1,1])
C0028778 (UMLS CUI [1,2])
Pregnancy | Breast Feeding
Item
5. women who are pregnant or breast feeding
boolean
C0032961 (UMLS CUI [1])
C0006147 (UMLS CUI [2])
Allergic reaction to iodinated contrast material
Item
6. allergy to iodinated contrast used for angiography
boolean
C2215738 (UMLS CUI [1])
Tumor Burden Liver Percentage
Item
7. tumour burden of more than 50% of liver
boolean
C1449699 (UMLS CUI [1,1])
C0023884 (UMLS CUI [1,2])
C0439165 (UMLS CUI [1,3])
Signs Bacterial Infections | Signs Virus Diseases | Signs HIV Infections | Signs Mycoses
Item
8. patients with objective signs of active bacterial, viral (hiv), or fungal infection
boolean
C0311392 (UMLS CUI [1,1])
C0004623 (UMLS CUI [1,2])
C0311392 (UMLS CUI [2,1])
C0042769 (UMLS CUI [2,2])
C0311392 (UMLS CUI [3,1])
C0019693 (UMLS CUI [3,2])
C0311392 (UMLS CUI [4,1])
C0026946 (UMLS CUI [4,2])
Cancer Other | Neoplasm Metastasis
Item
9. other primary malignancies or evidence of metastatic disease
boolean
C1707251 (UMLS CUI [1])
C0027627 (UMLS CUI [2])
Anthracyclines | Exception Doxorubicin
Item
10. patients previously treated with anthracyclines (other than doxorubicin).
boolean
C0282564 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C0013089 (UMLS CUI [2,2])
Comorbidity At risk Patient | Condition At risk Patient | Event At risk Patient | Comorbidity Excludes DEB-TACE | Condition Excludes DEB-TACE | Event Excludes DEB-TACE
Item
11. any co-morbid disease or condition or event that, in the investigator's judgment, would place the patient at undue risk that would preclude the safe use of deb-tace.
boolean
C0009488 (UMLS CUI [1,1])
C1444641 (UMLS CUI [1,2])
C0030705 (UMLS CUI [1,3])
C0348080 (UMLS CUI [2,1])
C1444641 (UMLS CUI [2,2])
C0030705 (UMLS CUI [2,3])
C0441471 (UMLS CUI [3,1])
C1444641 (UMLS CUI [3,2])
C0030705 (UMLS CUI [3,3])
C0009488 (UMLS CUI [4,1])
C0332196 (UMLS CUI [4,2])
C3273294 (UMLS CUI [4,3])
C3539919 (UMLS CUI [4,4])
C0348080 (UMLS CUI [5,1])
C0332196 (UMLS CUI [5,2])
C3273294 (UMLS CUI [5,3])
C3539919 (UMLS CUI [5,4])
C0441471 (UMLS CUI [6,1])
C0332196 (UMLS CUI [6,2])
C3273294 (UMLS CUI [6,3])
C3539919 (UMLS CUI [6,4])
Study Subject Participation Status | Clinical Trial Therapy Primary Malignant Liver Neoplasm
Item
12. under no circumstances should patients be enrolled in this study who is already participating in another study for treatment of primary liver cancer.
boolean
C2348568 (UMLS CUI [1])
C0008976 (UMLS CUI [2,1])
C0087111 (UMLS CUI [2,2])
C0024620 (UMLS CUI [2,3])
Embolotherapy Primary Malignant Liver Neoplasm | SIRT
Item
13. under no circumstances should patients be enrolled in this study who has received any other embolotherapy (including sirt) for the treatment of primary liver cancer.
boolean
C0013931 (UMLS CUI [1,1])
C0024620 (UMLS CUI [1,2])
C1831994 (UMLS CUI [2])